Limits...
Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus

Heterochromia due to unilateral therapy with travoprost in right eye.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401333&req=5

f4-opth-9-633: Heterochromia due to unilateral therapy with travoprost in right eye.

Mentions: It is not completely understood why PGs induce iris darkening and why this side effect is more common in patients with mixed-color irises than others. Increase in iris pigmentation is probably due to an increase in melanin content within cytoplasm of melanocytes,81,92 while an increase in melanocyte proliferation is unlikely. It has been demonstrated that PGF2α can stimulate, directly or indirectly, melanogenesis, probably though FP receptor action.93–95 Although iris pigmentation is thought to be only a cosmetic effect, it should be discussed with patients at the beginning of the therapy, especially in patients with mixed-color irises. Moreover, this side effect should always be evaluated when the patient needs a unilateral therapy, trying to avoid macroscopic differences between eyes (Figure 4).


Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure.

Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG - Clin Ophthalmol (2015)

Heterochromia due to unilateral therapy with travoprost in right eye.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401333&req=5

f4-opth-9-633: Heterochromia due to unilateral therapy with travoprost in right eye.
Mentions: It is not completely understood why PGs induce iris darkening and why this side effect is more common in patients with mixed-color irises than others. Increase in iris pigmentation is probably due to an increase in melanin content within cytoplasm of melanocytes,81,92 while an increase in melanocyte proliferation is unlikely. It has been demonstrated that PGF2α can stimulate, directly or indirectly, melanogenesis, probably though FP receptor action.93–95 Although iris pigmentation is thought to be only a cosmetic effect, it should be discussed with patients at the beginning of the therapy, especially in patients with mixed-color irises. Moreover, this side effect should always be evaluated when the patient needs a unilateral therapy, trying to avoid macroscopic differences between eyes (Figure 4).

Bottom Line: Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle.When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues.Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease.

View Article: PubMed Central - PubMed

Affiliation: Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy.

ABSTRACT
Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.

No MeSH data available.


Related in: MedlinePlus